enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. SGLT2 inhibitor - Wikipedia

   en.wikipedia.org/wiki/SGLT2_inhibitor

   Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors ...

3. Empagliflozin - Wikipedia

   en.wikipedia.org/wiki/Empagliflozin

   Empagliflozin lowers risk of hospitalization and death in people with reduced heart function, when added to standard heart failure treatment with or without type 2 diabetes. [ 29 ] [ 30 ] [ 31 ] It is indicated in adults with type 2 diabetes and established cardiovascular disease to reduce the risk of cardiovascular death; and as an adjunct to ...

4. GLP-1 receptor agonist - Wikipedia

   en.wikipedia.org/wiki/GLP-1_receptor_agonist

   GLP-1 agonists were developed initially for type 2 diabetes. [5] The 2022 American Diabetes Association (ADA) standards of medical care in diabetes include GLP-1 agonist or SGLT2 inhibitor as a first line pharmacological therapy for type 2 diabetes in patients who have or are at high risk for atherosclerotic cardiovascular disease or heart failure.

5. Merck (MRK) Heart Failure Drug Verquvo Gets Approval in Europe

   www.aol.com/news/merck-mrk-heart-failure-drug...

   Merck (MRK)/Bayer's (BAYRY) vericiguat gets approval for symptomatic chronic heart failure in patients with reduced ejection fraction in Europe.

6. FDA approves Novo Nordisk's Wegovy for use in reducing heart ...

   www.aol.com/news/fda-approves-novo-nordisks...

   Novo had at the time said it had filed for an expansion of Wegovy's approved use in the U.S. and Europe to include heart-disease treatment. The FDA's approval of the new cardiovascular indications ...

7. Dapagliflozin - Wikipedia

   en.wikipedia.org/wiki/Dapagliflozin

   Dapagliflozin is used along with diet, exercise, and usually with other glucose-lowering medications, to improve glycaemic control in adults with type 2 diabetes. . Dapagliflozin, in addition to other SGLT2-inhibitors, was shown to reduce the rate of decline in kidney function and kidney failure in non-diabetic and type 2 diabetic adults when added to the existing treatment

8. Wegovy Maker Novo Nordisk's Oral Diabetes Pill Cuts Heart ...

   www.aol.com/wegovy-maker-novo-nordisks-oral...

   On Monday, Novo Nordisk A/S (NYSE:NVO) released the headline results from the SOUL Phase 3 cardiovascular outcomes trial. Last year, Novo Nordisk’s subcutaneous once-weekly (injectable ...

9. Discovery and development of gliflozins - Wikipedia

   en.wikipedia.org/wiki/Discovery_and_development...

   Gliflozins are a class of drugs in the treatment of type 2 diabetes (T2D). They act by inhibiting sodium/glucose cotransporter 2 (SGLT-2), and are therefore also called SGLT-2 inhibitors. The efficacy of the drug is dependent on renal excretion and prevents glucose from going into blood circulation by promoting glucosuria. The mechanism of ...